Lorlatinib (Lorviqua) is an innovative kinase inhibitor targeting specific lung cancer biomarkers, approved for marketing by the U.S. FDA.

Indications for Lorlatinib (Lorviqua)

Primary Indications

Lorlatinib is mainly indicated for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC).

Patients with prior treatment failure: Disease progression occurs after treatment with crizotinib and at least one other ALK inhibitor.

Patients with first-line treatment failure: Disease progression occurs after initial treatment with alectinib or ceritinib as ALK inhibitors.

Specifications and Properties of Lorlatinib (Lorviqua)

Dosage Form and Specifications

Tablets: Available in two strengths: 25mg and 100mg.

25mg tablets: Round, tan film-coated tablets with a diameter of 8mm. One side is engraved with "Pfizer", and the other side is engraved with "25" and "LLN".

100mg tablets: Oval, pale purple film-coated tablets with dimensions of 8.5mm × 17mm, engraved with "Pfizer" and "LLN100".

Component Characteristics

Active Ingredient: Lorlatinib (chemical name: (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile).

Excipients: Microcrystalline cellulose, anhydrous calcium hydrogen phosphate, sodium carboxymethyl starch, magnesium stearate, etc. The coating contains hypromellose, lactose, polyethylene glycol, etc.

Physicochemical Properties

Appearance: White to off-white powder.

Solubility: pH-dependent solubility (32.38mg/mL at pH 2.55, 0.17mg/mL at pH 8.02).

Storage Methods for Lorlatinib (Lorviqua)

Routine Storage Conditions

Store at 20°C to 25°C; short-term temperature fluctuations between 15°C and 30°C are allowed during transportation.

Avoid humid environments; keep the original packaging sealed to prevent moisture absorption or photodegradation.

Usage Precautions

Administration Requirement: Swallow the tablets whole; do not chew, crush, or split them. Do not take if the tablet is broken.

Missed Dose Handling: If a dose is missed and more than 4 hours remain until the next scheduled dose, take the missed dose. Otherwise, skip the missed dose—do not take a double dose to make up for it.

Vomiting Handling: If vomiting occurs after taking the medication, do not take an additional dose; follow the original schedule for the next dose.

Special Reminder

Keep the medication out of the reach of children. Dispose of unused medication through professional drug recycling channels.